RT Journal Article
T1 GEIS guidelines for gastrointestinal sarcomas (GIST).
A1 Poveda, Andrés
A1 García Del Muro, Xavier
A1 López-Guerrero, Jose Antonio
A1 Cubedo, Ricardo
A1 Martínez, Virginia
A1 Romero, Ignacio
A1 Serrano, César
A1 Valverde, Claudia
A1 Martín-Broto, Javier
A1 GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research), 
K1 CD117
K1 DOG1
K1 GEIS
K1 GIST
K1 Imatinib
K1 KIT
K1 PDGFRA
K1 Regorafenib
K1 Sunitinib
AB Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1). On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum. GISTs have become a model of multidisciplinary work in oncology: the participation of several specialties (oncologists, pathologists, surgeons, molecular biologists, radiologists…) has forested advances in the understanding of this tumour and the consolidation of a targeted therapy, imatinib, as the first effective molecular treatment in solid tumours. Following its introduction, median survival of patients with advanced or metastatic GIST increased from 18 to more than 60months. Sunitinib and Regorafenib are two targeted agents with worldwide approval for second- and third-line treatment, respectively, in metastatic GIST.
YR 2017
FD 2017-03-02
LK http://hdl.handle.net/10668/11019
UL http://hdl.handle.net/10668/11019
LA en
DS RISalud
RD Apr 7, 2025